The U.S. National Institutes of Health is financing what's expected to be the largest long-term clinical study for an artificial pancreas to regulate the blood sugar levels in Type 1 diabetics to the tune of $12.7 million. This is the biggest chunk it's yet doled out as part of a program the agency started in 2014 to promote testing of artificial pancreas systems that's already backed at least three other research efforts.
High hopes for Chimerix's antiviral turned into a bad case of data shock Monday morning after the biotech revealed that brincidofovir had failed its first Phase III study. The stock instantly plunged, erasing 79% of its value by midmorning as investors absorbed the news of the setback and the company halted enrollment in two other late-stage transplant trials.
The companies say that these two Phase III studies bring the late-stage program up to 6 studies, meeting their goal for 2015.
Days after Sanofi received its first approval in Mexico for its pioneering dengue fever vaccine, it's said to be in discussions to bring the jab to India following a successful trial on an adult population there.
Bayer HealthCare has taken full control of the development of CGEN-15001T, an immune checkpoint inhibitor discovered by Compugen. The asset transfer triggered a $7.8 million (€7.1 million) milestone payment by Bayer, bringing the total pocketed by Compugen since it entered into the deal in 2013 up to $25 million.
Just three months after pulling the plug on its drug for NASH, Raptor Pharmaceutical says that it's pushing ahead with a pivotal study for a new drug to treat Huntington's, even though it failed the primary endpoint in a Phase II/III trial.
Cara Therapeutics said an oral version of its intravenous painkiller showed promise in a Phase II osteoarthritis study, clearing the way for further trials as the company targets a bevy of approvals.
U.K.-based Allergy Therapeutics is finally kicking off Phase II trials of its grass allergy vaccine in the U.S, announcing Monday that it has recruited its first trial participants. The trial will be a double-blind, placebo-controlled cumulative dose selection study.
A team from the Yale Cancer Center has devised a novel dosing schedule for flu vaccines aimed at increasing protection for cancer patients who are at a higher risk of contracting the viral infection.
Novavax has been on a roll with its RSV (respiratory syncytial virus) vaccine lately, landing an $89 million Gates Foundation grant, reporting promising Phase II results in infants and launching a Phase III trial in older adults. Now, the Gaithersburg, MD-based biotech is starting a second Phase III trial in pregnant women to gauge the vaccine's efficacy in infants through maternal immunization.